Cartesian Therapeutics Inc has a share price target of US$ 37, revenue growth forecast of -92.9%, and profit growth estimate of -4.2% for FY25, based on top 8 analyst calls.
Upgrade Your Plan
You need to upgrade your subscription plan to access this feature